Physician profile
Keith Wayne Schmidt
NPI 1407162746
$80,835.79
in general payments reported to CMS, 2019-2025
22 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $25K · 2021: $21K · 2022: $5,262 · 2023: $1,478 · 2024: $562 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Travel and Lodging: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.30 |
| Travel and Lodging | $221.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $40,076.14 | 2019-2025 | Proclaim, Eterna, Axium |
| Nevro Corp. | $28,314.03 | 2019-2024 | Senza, Nevro |
| Boston Scientific Corporation | $8,317.44 | 2019-2022 | |
| Vertiflex, INC. | $3,021.34 | 2019 | |
| Saluda Medical Americas, INC. | $255.94 | 2023 | Evoke Scs |
| Spr Therapeutics, INC | $144.49 | 2020-2024 | Sprint Pns System |
| Stryker Corporation | $139.06 | 2022 | |
| Medtronic USA, INC. | $72.20 | 2020 | |
| Vertos Medical, INC. | $69.57 | 2019-2024 | Mild Device Kit |
| Melinta Therapeutics, LLC | $67.17 | 2024-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Fresenius Kabi USA, LLC | $57.87 | 2025 | |
| Daiichi Sankyo INC. | $52.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.43 | 2023-2024 | Entyvio |
| Amgen INC. | $37.17 | 2020-2024 | Prolia, Evenity |
| Painteq LLC | $30.14 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.09 | 2023 | |
| Owp Pharmaceuticals, INC. | $25.34 | 2019 | |
| Aquestive Therapeutics, INC. | $19.57 | 2019 | |
| Ucb, INC. | $19.12 | 2019 | |
| Coherus Oncology, INC. | $17.29 | 2022 | |
| Stimwave Technologies Incorporated | $13.48 | 2019 | |
| Flowonix Medical Incorporated | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.